The in vitro activities of nine quinolones (seven fluoroquinolones, nalidixic acid, and acrosoxacin) against methicillin-resistant Staphylococcus aureus (MRSA) were compared with those of the glycopeptides teicoplanin and vancomycin. MICs against 160 strains of ciprofloxacin-susceptible (MIC, <2.0 ,ug/ml) MRSA and 40 strains of ciprofloxacin-resistant (MIC, .2.0 tig/ml) MRSA were determined. The following MICs for 50% of the strains tested (in micrograms per milliliter) were obtained for ciprofloxacin-susceptible and -resistant strains, respectively: tosufloxacin, 0.06 and 2.0; ofloxacin, 0.25 and 16; ciprofloxacin, 0.5 and 16; pefloxacin, 0.5 and 32; acrosoxacin, 1.0 and >256; enoxacin, 1.0 and 64; fleroxacin, 1.0 and 32; norfloxacin, 2.0 and 64; nalidixic acid, 64 and 512; teicoplanin, 1.0 and 1.0; vancomycin, 2.0 and 2.0. In mutation rate studies using a range of antibiotic concentrations to reflect those achievable in vivo, resistant mutants grew only on plates containing nalidixic acid (rate of mutation to resistance, 10-7 to 10-8) and on plates containing low concentrations of ciprofloxacin, enoxacin, and norfloxacin (rate of mutation to resistance, 10-8 to 10-9). In time-kill studies, 99.9% killing was found within 8 h for all of the quinolones tested (norfloxacin and nalidixic acid were not tested). Teicoplanin and vancomycin were less rapidly bactericidal. For the clinical isolates of ciprofloxacin-resistant MRSA, different levels and patterns of quinolone resistance were found. Generally, cross-resistance among the fluoroquinolones was complete; however, incomplete cross-resistance did occur with the nonfluorinated quinolone acrosoxacin.
and streptomycin (19) . The choices for treatment of infections due to MRSA are few, and in the absence of susceptibility testing data or in serious infections, vancomycin is regarded as the antibiotic of choice for treatment (12) .
Nalidixic acid, the first quinolone agent to be developed, was active only against enterobacteria and possessed pharmacokinetics which restricted its use to treatment of urinary tract infections. In the 1980s, a new generation of quinolones, the fluoroquinolones, was introduced. These had broad-spectrum bactericidal activity, achieved satisfactory levels in serum and tissue, and because of their unique mode of action, were not affected by mechanisms of resistance to other antimicrobial agents (27) . The properties of these agents have recently been reviewed by Wolfson and Hooper (35) . Because of the differences in potency and pharmacokinetics (5, 13) among quinolones, the class-testing approach is Compared with vancomycin, fluoroquinolones are relatively nontoxic and offer clinicians a choice between oral and parenteral administration for systemic infections. Another new glycopeptide antibiotic, teicoplanin, has recently entered clinical use. This antibiotic can be administered parenterally, and it is believed to be less toxic than vancomycin (34) .
This work compares the in vitro activities of the quinolones with those of teicoplanin and vancomycin with a view to the use of quinolones as alternatives to the glycopeptide antibiotics. For a comprehensive assessment, these compounds were tested against a collection of 200 strains of MRSA derived from 38 centers distributed throughout 26 countries.
MATERIALS AND METHODS
Strains. The S. aureus isolates used in this study were all catalase-positive, tube coagulase-positive, DNase-positive, gram-positive cocci. The strains were obtained from one center each in Australia, Austria, Belgium, Brazil, Chile, Denmark, the Federal Republic of Germany, Finland, the German Democratic Republic, Greece, Hong Kong, Italy, Japan, Kuwait, Poland, Portugal, Switzerland, Turkey, and the USSR; two centers each in France, Israel, the Republic of Ireland, South Africa, and Spain; three in England, and six in the United States.
For logistic reasons, only four selected methicillin-resistant strains (from different continents) were used in the time-kill and mutation rate studies. These were strains RM1, SA1, AUS10, and RL7, which were Resistance to methicillin was determined by streaking isolates and appropriate controls onto nutrient agar (Oxoid, Basingstoke, England) and then placing paper strips containing 25 ,ug of methicillin (Mast Laboratories, Merseyside, England) at right angles to the inocula. These plates were then incubated for 40 h at 30°C, and strains were designated methicillin resistant if they grew within 3 mm or less of the edge of the strip.
Killing curves. For acrosoxacin, ciprofloxacin, enoxacin, fleroxacin, ofloxacin, pefloxacin, tosufloxacin, teicoplanin, and vancomycin, timed killing curves were determined with five selected strains. The strains were grown for 24 h at 37°C in 10 ml of Iso-Sensitest broth, and 0.5-ml samples were used to inoculate Erlenmeyer flasks (500 ml) containing various concentrations of the test substances in 100 ml of IsoSensitest broth. For all killing studies, an initial broth concentration of 5.0 x 105 to 1.0 x 107 CFU/ml was used.
These flasks, along with control flasks to which no agent had been added, were placed in an orbital incubator (Gallenkamp, Loughborough, England) and shaken at 100 rpm for 24 h at 37°C. Quantitative bacterial counts at 0, 4, 8, and 24 h of exposure to the agents were performed by spreading 0.1 ml on Iso-Sensitest agar plates which were incubated for 24 h at 37°C before counting.
The lowest number of bacteria for which our viable counting technique could reliably be used was 200 CFU/ml (i.e., 20 colonies on a neat plate); hence, a cutoff point of log1o 2.3 was used for the graphs shown (see Fig. 1 ). To assess the influence of antibiotic carryover on the viable counts observed, 0.1-ml samples of neat preinoculation broth and 10-fold dilutions of antibiotic-containing preinoculation broth were spread on Iso-Sensitest agar plates which were then inoculated with approximately 50 CFU by spreading 0.1 ml of an appropriate dilution of a 24-h-old broth culture of S. aureus NCTC 6571 (strain SOX). Viable counts were determined after 24 h of incubation at 37°C and compared with those on non-antibiotic-containing plates. No significant reduction in counts was seen on any of the antibiotic-containing plates as calculated with Student's t test (P > 0.9).
The following agents at the indicated concentrations (micrograms per milliliter) were used in the time-kill studies: acrosoxacin, 4.0; ciprofloxacin, 3.0; enoxacin, 10; fleroxacin, 5.0; ofloxacin, 8.0; pefloxacin, 8.0; tosufloxacin, 0.25; teicoplanin, 16; vancomycin, 16. These concentrations were chosen to reflect the attainable levels of these agents in serum.
Mutation rates. Cultures of the selected strains were grown in 10 ml of Iso-Sensitest broth at 37°C for 18 to 22 h. These were centrifuged and suspended in 2 ml of phosphatebuffered saline. Samples (0.1 ml) were spread on Iso-Sensitest agar plates containing various concentrations of antimicrobial agents. These plates were incubated for 48 h at 37°C and read at 24 and 48 h. Colonies which grew on these plates were picked off and reidentified as S. aureus by the criteria given previously, and development of resistance was confirmed by determination of MICs.
The following drugs at the indicated concentrations (micrograms per milliliter) were used: acrosoxacin, 10 and 50; ciprofloxacin, 5.0 and 25; enoxacin, 10 and 50; fleroxacin, 10 and 50; ofloxacin, 5.0 and 25; nalidixic acid, 256; norfloxacin, 10 and 50; pefloxacin, 5.0 and 25; tosufloxacin, 0.5 and 2.5; teicoplanin, 5.0 and 25; vancomycin, 10 and 50. These concentrations represented 1Ox and 25x, respectively, the MICs of the agents against MRSA.
RESULTS
Susceptibility results. For this study, 200 strains from 38 centers in 26 countries were preliminarily screened for susceptibility to ciprofloxacin. As a result, 160 isolates were found to be susceptible (MIC, <2 ,ug/ml) and 40 were found to be resistant (MIC, .2 ,ug/ml) to ciprofloxacin. Table 1 summarizes our findings on the susceptibilities of the 160 ciprofloxacin-susceptible isolates to a further eight different quinolones and the glycopeptides teicoplanin and vancomycin. The susceptibilities of the 40 ciprofloxacin-resistant strains to the other quinolones and the glycopeptides are also shown in Table 1 . Teicoplanin and vancomycin were both equally active against the ciprofloxacin-susceptible and -resistant isolates. The quinolones tested possessed a range of activities against the ciprofloxacin-susceptible MRSA isolates tested; the most active quinolone was tosufloxacin (MIC for 50% of the strains tested, 0.06 p.g/ml), and the least active quinolone was nalidixic acid (MIC for 50% of the strains tested, 64 ,ug/ml). Ofloxacin was the most active of the clinically available fluoroquinolones, followed closely by ciprofloxacin and pefloxacin; many strains were susceptible to concentrations of these agents of 1.0 pg/ml or lower.
Against the 40 strains of ciprofloxacin-resistant MRSA, tosufloxacin was the most active quinolone, followed by ciprofloxacin and ofloxacin. Different patterns and levels of quinolone resistance were seen among the strains of ciprofloxacin-resistant MRSA tested, and examples of these patterns and the origins of the strains possessing them are shown in Table 2 . The pattern of elevations in MICs was unfixed among the quinolones, and the order of the potencies of the agents varied from strain to strain. Differences in activity between acrosoxacin and ciprofloxacin were particAlthough ciprofloxacin and enoxacin were initially bacteularly notable; some strains were similarly susceptible to ricidal against strain RL7, after 24 h of incubation, regrowth both agents, whereas others were highly resistant to achad occurred (Fig. 1A and D) . Initially, the MIC of ciprorosoxacin only.
floxacin for strain RL7 was 1.0 jig/ml; however, the MIC of Rates of killing. The rates of killing produced by ciprofloxciprofloxacin for the organisms regrowing in ciprofloxacin acin, enoxacin, ofloxacin, pefloxacin, teicoplanin, and van-(3.0 jig/ml) broth and enoxacin (10 ,ug/ml) broth was 16.0 comycin against the selected methicillin-resistant strains and ,ug/ml. The susceptibilities of the regrowing strains to varithe susceptible control strain are shown in Fig. 1 . The ous quinolones are shown in Table 3 . Although some reconcentrations of quinolones and glycopeptides used for the growth was seen with the other strains, no visible turbidity time-kill studies were chosen to reflect the maximum levels appeared in the broths after 36 h of incubation and no attainable in blood. With these agent concentrations, the increase in the ciprofloxacin MIC was found for the organquinolones-ciprofloxacin, enoxacin, ofloxacin, and pefloxisms isolated from these broths. The initial ciprofloxacin acin-caused 99.9% killing after 8 h (Fig. 1A to D) . AcrosoxMICs for strains RM1, SA1, AUS10, and SOX were 0.5, 0.5, acin, fleroxacin, and tosufloxacin also produced 99.9% kill-0.5, and 0.25 p.g/ml, respectively. ing after 8 h at the concentrations tested (data not shown).
Mutation rates. The largest inoculum that could be used The glycopeptides teicoplanin and vancomycin ( Fig. 1E and for the mutation rate studies was approximately 1.0 x 109 F) were less rapidly bactericidal; however, both agents CFU, because denser inocula overgrew on some of the produced 99.9% reduction of the original inocula of all five plates containing lower concentrations of the quinolones. strains after 24 h.
Low rates of mutation to resistance were found for strain 16 ,ug/ml (E), and teicoplanin at 16 ,ug/ml (F) against representative MRSA strains from the United States (RM1), South Africa (SA1), Australia (AUS10), and England (RL7) and S. aureus NCTC 6571 (SOX), a methicillin-and penicillin-susceptible control strain.
RL7 in the presence of ciprofloxacin at 5.0 p.g/ml (3.0 x 10-8) and enoxacin at 10 ,ug/ml (5.0 x 10-8) and for strains RM1 (3.0 x 10-9) and SAl (5.0 x 10-9) in the presence of norfloxacin at 10 p.g/ml. Rates of mutation to resistance of 10-7 to 10-8 were found for the strains in the presence of nalidixic acid at 250 ,g/ml. MIC testing revealed that all of the mutants had decreased susceptibilities to the agents used to select for resistance, and the results for strain RL7 are shown in Table 3 . The resistant mutants of strain RL7 which grew in the presence of either ciprofloxacin or enoxacin possessed cross-resistance to the other fluoroquinolones; however, the mutants which grew in the presence of nalidixic acid at 250 ,ug/ml failed to show cross-resistance to the fluoroquinolones.
DISCUSSION
Against the ciprofloxacin-susceptible MRSA strains, we found ciprofloxacin, ofloxacin, and pefloxacin to be equally highly active. Enoxacin, fleroxacin, and norfloxacin showed less activity, and nalidixic acid possessed little activity. Such findings for S. aureus are in general agreement with those reported by other workers (1, 22, 23, 29, 35) . Tosufloxacin was the most active of the quinolones tested, which is in accordance with the findings of Barry and Jones (2) ; detailed reports of the clinical suitability of this compound are awaited.
Another interesting finding from susceptibility testing against ciprofloxacin-susceptible MRSA strains was the high Another interesting finding following susceptibility testing of ciprofloxacin-resistant MRSA was incomplete cross-resistance between the fluoroquinolones and acrosoxacin in a few strains. Such reversed, incomplete cross-resistance has been previously reported only for a strain of Flavobacterium multivorans (32a) and may indicate a novel resistance mechanism. Generally, cross-resistance among the fluoroquinolones and other quinolones was complete, and these findings agree with those of other workers (17) .
The fluoroquinolones tested in our time-kill studies were bactericidal, and it is well known that members of this class of agents are characteristically bactericidal (23, 29) . Teicoplanin and vancomycin are also bactericidal (20) , although killing seems to be slower than that seen with the fluoroquinolones. In our time-kill studies, strain RL7 overgrew in the presence of ciprofloxacin and enoxacin, and organisms with reduced susceptibilities were isolated from these broths. Foster et al. (9) compared the in vitro activities of quinolone antibiotics and vancomycin against gentamicin-resistant MRSA by time-kill studies and reported overgrowth of S. aureus in the presence of broth containing ciprofloxacin. Unlike those researchers, we found no regrowth with vancomycin in our time-kill studies.
In the mutation rate studies, strain RL7 had a relatively high rate of mutation to ciprofloxacin and enoxacin resistance. This may explain the overgrowth of this strain in the ciprofloxacin and enoxacin time-kill studies, especially as the development of quinolone resistance has been reported to be due to single-step mutations (15) . A notable property of the fluoroquinolones is the reported low rate of bacterial mutation to resistance (6) . This contrasts with nalidixic acid, the use of which was restricted by the emergence of nalidixic acid-resistant mutants (24) . In vitro selection of resistance to vancomycin is very difficult with staphylococci (10), and no clinical isolates of S. aureus resistant to this agent have been reported. Watanakunakorn (33) has found it easier to induce resistance to teicoplanin; however, we obtained no isolates resistant to teicoplanin, and for both agents we failed to isolate resistant mutants in the time-kill or mutation rate studies.
Disturbing levels of quinolone resistance in MRSA have been reported (18) , and a number of workers have reported outbreaks of infection due to ciprofloxacin-resistant MRSA (25, 26) . Although the fluoroquinolones are rapidly bactericidal, mutation to resistance can occur, resulting in overgrowth in vitro. To prevent further emergence of staphylococcal fluoroquinolone resistance, we strongly recommend that fluoroquinolones be used only in combination with unrelated agents to minimize selection of resistant mutants. Encouraging clinical results have been obtained with ciprofloxacin and rifampin in combination (7) . Furthermore, there is evidence that all quinolones are not equal in antistaphylococcal activity and potential to select resistant strains (28) . Fluoroquinolones under development, such as tosufloxacin and AT-4140 (16), may prove to be much more potent against S. aureus than those currently available. Until our understanding of how fluoroquinolone resistance develops and spreads is more complete, it would be appropriate to use fluoroquinolones with restraint.
To conclude, we believe that fluoroquinolones are potentially useful agents for treatment of staphylococcal infections, especially as new, even more active agents, such as tosufloxacin, are in the process of development. It is most VOL. 35, 1991 
